Alembic Receives FDA Approval for Valganciclovir Solution
The oral solution is approved for treating CMV retinitis in patients with AIDS and preventing CMV disease in transplant patients.
Updated on Oct. 28, 2026 in Cancer
Live Poll
Do you support the increased availability of generic medications to help lower prescription drug costs?
The US FDA has granted final approval to Alembic Pharmaceuticals Limited for a 50 mg/mL valganciclovir oral solution. This medication is therapeutically equivalent to Valcyte, which is manufactured by Cheplapharm Arzneimittel GmbH.
Why it matters
This approval provides a new generic option for patients requiring valganciclovir to manage CMV retinitis associated with AIDS or to prevent CMV complications in organ transplant recipients.
Alembic now holds 247 cumulative ANDA approvals from the US FDA, comprised of 227 final and 20 tentative authorizations. The approved oral solution is formulated at a 50 mg/mL dosage.
The players
Alembic Pharmaceuticals Limited
This is a pharmaceutical company that develops and manufactures a wide range of generic and branded drugs for global markets.
US FDA
The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of medical products.
Cheplapharm Arzneimittel GmbH
This company is a German pharmaceutical firm that specializes in the acquisition and distribution of established legacy drug brands.
The details
Alembic Pharmaceuticals submitted an Abbreviated New Drug Application to secure this regulatory clearance for the treatment. The medication acts as a generic equivalent to the reference drug, Valcyte, produced by Cheplapharm Arzneimittel GmbH.
Timeline
Alembic Pharmaceuticals received the final US FDA approval on October 28, 2026.
Health Landscape
This approval follows the regulatory pathway established by the Hatch-Waxman Act, which encourages the development and market entry of generic medications. Such approvals shift the landscape by introducing more cost-effective therapeutic alternatives to legacy treatments.
Patients requiring treatment for CMV retinitis or organ transplant-related CMV disease gain access to a new generic therapy option. This development may offer medical providers more flexibility in prescribing treatment plans for those managing chronic conditions.
The takeaway
The addition of this generic valganciclovir solution increases the supply of essential medications for immunocompromised patients. Healthcare providers can integrate this new equivalent into existing protocols for managing CMV-related health risks.
Further reading
For broader information on current medical treatments, explore the Cancer section.
Source note: This article includes information reported by Pharmabiz.
Live Poll
Do you support the increased availability of generic medications to help lower prescription drug costs?
